论文部分内容阅读
目的探讨经直肠超声引导下~(125)I粒子植入治疗前列腺癌患者术后血清前列腺特异抗原(PSA)变化及影响治疗效果的危险因素。方法 70例经直肠超声引导下~(125)I粒子植入治疗的前列腺癌患者,依随访结果分为A组(良性反弹组,32例),B组(生化复发组,12例),C组(疗效稳定组,26例)。比较三组PSA的变化及影响治疗效果的危险因素。结果 A组复查血PSA降至最低值后开始升高时间发生在术后(16.5±1.3)个月,且65.6%(21/32)出现于14~27周;B组复查血PSA降至最低值后开始升高时间发生在术后(29.7±2.2)个月;C组复查血PSA降至最低值时后长期保持稳定。治疗时患者年龄是良性反弹的危险因素(OR=0.802,P=0.0025<0.01)。结论超声引导下~(125)I粒子植入治疗前列腺癌术后监测血PSA变化有助于临床对治疗效果的评估。
Objective To investigate the changes of postoperative serum PSA and the risk factors for the therapeutic effect of transrectal ultrasound guided 125I seed implantation in patients with prostate cancer. Methods Seventy patients with prostate cancer treated with ~ (125) I particle implantation guided by rectal ultrasound were divided into group A (benign bounce group, n = 32), group B (group of biochemical recurrence, n = 12) Group (stable effect group, 26 cases). The changes of PSA in three groups and the risk factors affecting the treatment effect were compared. Results After the blood PSA level dropped to the lowest level in group A, the time to start rising was 16.5 ± 1.3 months after operation and 65.6% (21/32) occurred in 14 to 27 weeks. The blood PSA level in group B was the lowest Value began to rise after the operation occurred in (29.7 ± 2.2) months; C group after the return of blood PSA to a minimum of long-term stability. Patient age at treatment was a risk factor for benign rally (OR = 0.802, P = 0.0025 <0.01). Conclusion Ultrasound-guided ~ (125) I particle implantation in the treatment of prostate cancer postoperative monitoring of serum PSA changes in clinical evaluation of the treatment effect.